News and Trends 30 Nov 2022
TrialSpark acquires immunodermatology portfolio and creates Libertas Bio
TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes…